A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
نویسندگان
چکیده
منابع مشابه
The incidence of hyperglycemia during the induction phase of chemotherapy in patients with acute lymphoblastic leukemia
Background: Hyperglycemia is one of the most complications of corticosteroid and asparaginase during induction phase of chemotherapy in children suffering from acute lymphoblastic leukemia (ALL). This study was carried out to evaluate the incidence of hyperglycemia and associated risk factors during chemotherapy induction phase at Amirkola Children's Hospital. Materials and Methods: In this c...
متن کاملExpression of ROR1 Gene in Patients with Acute Lymphoblastic Leukemia
Background: Acute lymphoblastic leukemia (ALL) results from genetic alterations in a single lymphoid progenitor cell. Expression of ROR1 is reported to be increased in ALL and mantle cell lymphoma. In this study the expression of ROR1 was assessed in newly diagnosed patients with ALL. Methods: This study was carried out on 40 patients with newly diagnosed ALL and healthy individuals as contro...
متن کاملThe mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
Therapeutic options are limited in relapsed/refractory acute myeloid leukemia (AML). We evaluated the maximum tolerated dose (MTD) and preliminary efficacy of mammalian target of rapamycin (mTOR) inhibitor, everolimus (days 5-21) in combination with azacitidine 75 mg/m2 subcutaneously (days 1-5 and 8-9 every 28 days) in 40 patients with relapsed (n = 27), primary refractory (n = 11) or elderly ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2015
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-14-2888